Home LiteratureArticle Details
PMID: 10791988 Published · ppublish English Journal Article Review

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

The Journal of clinical investigation ·Vol. 105 ·No. 9 ·2000-05-00 ·Pages 1169-72

Hermiston T

Abstract

暂无摘要

MeSH Terms
Antineoplastic Agents/therapeutic use Gene Targeting/methods Genetic Therapy/methods Genetic Vectors Transgenes Virus Replication Viruses/genetics,growth & development,immunology
Chemicals
Antineoplastic Agents
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Hermiston T
Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94925, USA. thermiston@onyx-pharm.com
References (39)
39 references, click to expand
  1. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization.
    Hum Gene Ther. 2000 Jan 1;11(1):67-76 PMID: 10646640
  2. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
    J Virol. 1999 Sep;73(9):7556-64 PMID: 10438845
  3. Conditionally replicating herpes vectors for cancer therapy.
    J Clin Invest. 2000 Apr;105(7):841-6 PMID: 10749560
  4. Replication-selective adenoviruses as oncolytic agents.
    J Clin Invest. 2000 Apr;105(7):847-51 PMID: 10749561
  5. Prodrug-activating systems in suicide gene therapy.
    J Clin Invest. 2000 May;105(9):1161-7 PMID: 10791987
  6. Immunomodulation of cancer: potential use of selectively replicating agents.
    J Clin Invest. 2000 May;105(9):1173-6 PMID: 10791989
  7. Regulatable systems: applications in gene therapy and replicating viruses.
    J Clin Invest. 2000 May;105(9):1177-83 PMID: 10791990
  8. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome.
    J Virol. 1973 Sep;12(3):643-52 PMID: 4355861
  9. Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells.
    J Virol. 1975 Sep;16(3):662-73 PMID: 169392
  10. Isolation of deletion and substitution mutants of adenovirus type 5.
    Cell. 1978 Jan;13(1):181-8 PMID: 620421
  11. Generation of adenovirus by transfection of plasmids.
    Nucleic Acids Res. 1983 Sep 10;11(17):6003-20 PMID: 6310523
  12. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.
    Virology. 1987 Jan;156(1):107-21 PMID: 2949421
  13. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.
    Science. 1990 Nov 30;250(4985):1262-6 PMID: 2173860
  14. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
    Nature. 1992 May 7;357(6373):82-5 PMID: 1533443
  15. Packaging capacity and stability of human adenovirus type 5 vectors.
    J Virol. 1993 Oct;67(10):5911-21 PMID: 8371349
  16. Tolerance, danger, and the extended family.
    Annu Rev Immunol. 1994;12:991-1045 PMID: 8011301
  17. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.
    Nat Med. 1995 Sep;1(9):938-43 PMID: 7585221
  18. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
    Science. 1996 Oct 18;274(5286):373-6 PMID: 8832876
  19. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity.
    Hum Gene Ther. 1997 Jan 1;8(1):73-85 PMID: 8989997
  20. Replicating viruses as selective cancer therapeutics.
    Mol Med Today. 1996 Dec;2(12):519-27 PMID: 9015793
  21. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
    Nat Med. 1997 Jun;3(6):639-45 PMID: 9176490
  22. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
    Cancer Res. 1997 Jul 1;57(13):2559-63 PMID: 9205053
  23. Gene therapy -- promises, problems and prospects.
    Nature. 1997 Sep 18;389(6648):239-42 PMID: 9305836
  24. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.
    Curr Opin Immunol. 1999 Aug;11(4):380-6 PMID: 10448144
  25. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
    Cancer Res. 1999 Aug 15;59(16):3861-5 PMID: 10463570
  26. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
    Cancer Res. 1999 Sep 1;59(17):4200-3 PMID: 10485454
  27. The Seattle Virus Watch. VII. Observations of adenovirus infections.
    Am J Epidemiol. 1977 Apr;105(4):362-86 PMID: 192073
  28. Gene therapy.
    Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12744-6 PMID: 9398067
  29. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
    Hum Gene Ther. 1997 Nov 20;8(17):2057-68 PMID: 9414254
  30. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.
    Gene Ther. 1998 Jan;5(1):121-30 PMID: 9536273
  31. Human gene therapy.
    Nature. 1998 Apr 30;392(6679 Suppl):25-30 PMID: 9579858
  32. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
    Nat Biotechnol. 1998 May;16(5):444-8 PMID: 9592392
  33. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy.
    Hum Gene Ther. 1998 Jun 10;9(9):1323-33 PMID: 9650617
  34. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
    Ann Surg. 1998 Sep;228(3):366-74 PMID: 9742919
  35. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy.
    Clin Cancer Res. 1997 Nov;3(11):2081-8 PMID: 9815600
  36. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.
    Cancer Res. 1999 Jan 15;59(2):410-3 PMID: 9927055
  37. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.
    Hum Gene Ther. 1999 Feb 10;10(3):385-93 PMID: 10048391
  38. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.
    Gene Ther. 1999 Jan;6(1):57-62 PMID: 10341876
  39. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
    Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13 PMID: 10681459
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI9973
Email
thermiston@onyx-pharm.com
Published
2000-05-00
Pages
1169-72
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC315451
Subset
IM
External Links
PubMed source DOI: 10.1172/JCI9973 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2